<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01057160</url>
  </required_header>
  <id_info>
    <org_study_id>MK 462</org_study_id>
    <nct_id>NCT01057160</nct_id>
  </id_info>
  <brief_title>Rizatriptan 10 MG RPD in the Treatment of Acute Migraine</brief_title>
  <acronym>Rinotama</acronym>
  <official_title>A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universität Duisburg-Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universität Duisburg-Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre, open label, prospective, randomized, two-attack study with active
      comparator in patients reporting inadequate response to analgesics and/or triptans to examine
      the efficacy of Rizatriptan 10 mg RPD in this group of patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with headache response on a one to four scale after 2 hours.</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients being headache free two hours after intake of study medication. Time of dosing to onset of headache relieve. Relief of concomitant symptoms. Rate of sustained pain free Percentage of patients needing rescue medication</measure>
    <time_frame>(time points 0.5, 1, 1.5, 2, 4, 8, 12, 24 hours after drug intake</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>intake of rizatriptan 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>previous used analgesic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rizatriptan</intervention_name>
    <description>use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic</description>
    <arm_group_label>intake of rizatriptan 10 mg</arm_group_label>
    <arm_group_label>previous used analgesic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's signature on the informed consent document [each patient should be given
             ample time to read (or have read to them) the consent form, ask any questions they may
             have regarding the trial and have a clear understanding of the trial and the
             procedures involved prior to the signing of the consent form].

          -  Have a clinical diagnosis of migraine with or without aura according to IHS criteria
             at least one year prior to enrollment.

          -  At screening at least two migraine attacks per month and no more than ten during the
             last three months prior to inclusion.

          -  At screening a stable dose of prophylactic medication (including no prophylactic
             treatment) for at least two months and no change of prophylactic medication during
             active trial period.

        Exclusion Criteria:

          -  Contraindication to triptans or Rizatriptan according to medical information sheet.

          -  Patient has a history or clinical evidence of ischemic heart disease (e.g., angina
             pectoris of any type, history of myocardial infarction or documented silent ischemia)
             or symptoms or findings consistent with ischemic heart disease, coronary artery
             vasospasm (including Prinzmetal's variant angina), or other significant underlying
             cardiovascular disease. Patient has uncontrolled hypertension. Patient has either
             demonstrated hypersensitivity to or experienced a serious adverse event in response to
             Rizatriptan or any of its inactive ingredients.

          -  History of treatment failure for at least one triptan for the treatment of acute
             migraine attacks.

          -  Any other headache, except tension type headache on 5 or less days a month within
             three months prior to screening.

          -  A history of drug induced headache, medication overuse headache or any other
             addiction.

          -  Any history of allergic hypersensitivity or poor tolerance to any components of the
             preparations used in this trial.

          -  Females of childbearing potential not using reliable means of birth control, pregnant
             or lactating females or expected/ planned pregnancy.

          -  Participation (planned or current) in any investigational drug or device trial within
             the previous 30 days prior to screening visit.

          -  Inability to understand the trial procedures, and thus inability to give informed
             consent.

          -  History of allergy to sulfa drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Christoph Diener, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, University Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2010</study_first_submitted>
  <study_first_submitted_qc>January 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2010</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universität Duisburg-Essen</investigator_affiliation>
    <investigator_full_name>Hans-Christoph Diener</investigator_full_name>
    <investigator_title>Prof. of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

